Go Pro
NASDAQ:SEPN

Septerna Q1 2026 Earnings Report

Septerna logo
$38.51 +0.76 (+2.01%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$38.88 +0.37 (+0.95%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Septerna EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.42
Beat/Miss
Beat by +$0.23
One Year Ago EPS
N/A

Septerna Revenue Results

Actual Revenue
$26.52 million
Expected Revenue
$16.98 million
Beat/Miss
Beat by +$9.55 million
YoY Revenue Growth
N/A

Septerna Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Monday, May 11, 2026
Conference Call Time
4:00PM ET

Upcoming Earnings

Septerna's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Septerna Earnings Headlines

Septerna to Participate in Upcoming Investor Conferences
Elon Musk’s Hushed FCC Filing. Sept 25th.
Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the largest markets in the world. James Altucher, who previously flagged Nvidia in 2008 and Bitcoin in 2013, says the filing could rival Tesla, SpaceX and xAI combined. Few investors know this filing exists, but that is expected to change quickly.tc pixel
Septerna names Rajiv Patni as CMO
See More Septerna Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Septerna? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Septerna and other key companies, straight to your email.

About Septerna

Septerna (NASDAQ:SEPN) is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in numerous biological processes and are established targets for therapies across a range of diseases.

The company uses its proprietary Native Orthosteric Ligand Discovery platform to study GPCRs in their native cellular environments and identify small-molecule compounds that can modulate these receptors. Septerna’s research and development efforts are directed toward potential treatments in areas including immunology, inflammation, metabolic disease and other conditions with significant unmet medical needs.

Septerna was founded to advance GPCR-directed drug discovery and became a publicly traded company on the Nasdaq under the symbol SEPN. The company is based in the United States and is focused primarily on advancing its internal discovery and clinical-stage pipeline rather than marketing approved products.

View Septerna Profile